Palatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) announced its participation in the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020, at 4:00 p.m. EDT, through a virtual presentation. Carl Spana, President and CEO, will discuss the company's corporate and development updates. Interested parties can access the webcast via the official website or by following the provided link. The presentation will be available for replay for 90 days.
Details
News Market Reaction – PTN
The recorded move for PTN in the trading session of this news was -2.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced today that it will be presenting at the H.C. Wainwright & Co., 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 4:00 p.m. EDT. The conference will be held virtually.
Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.
The presentation will be webcast and can be accessed by logging on to the "Investor/Webcasts" section of Palatin's website at http://www.palatin.com or by clicking the following link: https://wsw.com/webcast/hcw7/ptn/1491682. The webcast will be available for 90 days.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-to-present-at-the-hc-wainwright--co-22nd-annual-global-investment-conference-301128027.html
SOURCE Palatin Technologies, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.